Aripiprazole – Mechanism of Action, Psychopharmacology and Clinical Application

Posted on:October 23, 2020
Last Updated: October 26, 2020
Time to read: 7 minutes

Aripiprazole is an achiral quinolinone derivative and a second-generation antipsychotic that was approved for the treatment of schizophrenia in 2002.

Aripiprazole is marketed as Abilify and comes in oral tablets (2, 5, 10, 15, 20, and 30 mg doses), orally disintegrating tablets (10 and 15 mg doses), an oral solution (1 mg/mL), and as an intramuscular injection (7.5 mg/mL).

References